Delivery Order SPE2DR25D1053-SPE2DR26FT089
- Not listed
- The Defense Logistics Agency awarded a $43,110.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with final delivery required by July 15, 2025. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery at its corporate office location. This delivery order is issued...
- The Defense Logistics Agency awarded a $2,416.05 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 29, 2025. This non-competitive delivery order was placed against AmerisourceBergen's broader pharmaceutical supply contract vehicle and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune...
- The Defense Logistics Agency awarded a delivery order valued at $13,700.16 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price contract requires no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely prescribed biologic medication used to treat various inflammatory conditions,...
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded contract employs firm fixed price pricing with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. HUMIRA is a biologic medication commonly used...
- The Defense Logistics Agency awarded a delivery order valued at $12,823.53 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on September 12, 2025, with an ultimate completion date of September 15, 2025. This is a firm fixed price, non-competitive delivery order with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. HUMIRA is a widely used...
- The Defense Logistics Agency has awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA Pen 40 mg/0.8 mL units. This competitively awarded, firm fixed price contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic medication for treating autoimmune conditions including rheumatoid arthritis,...
- The Defense Logistics Agency awarded a delivery order valued at $13,628.78 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL units. This competitively awarded, firm fixed-price delivery order was executed on September 25, 2025, with an ultimate completion date of September 26, 2025. The contractor will perform this work from its corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic immunosuppressant medication indicated for multiple...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL with a ceiling value of $1,142.05. This is a firm fixed-price delivery order with no set-aside designation, executed under competitive procedures. The contract is scheduled for completion by September 17, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a biologic...
- The Defense Logistics Agency awarded a $2,265.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 28, 2025, with an ultimate completion date of August 29, 2025. This non-set-aside contract represents a pharmaceutical supply delivery under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery location is...
- The Defense Logistics Agency awarded a delivery order valued at $16,470.37 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on September 8, 2025, with an ultimate completion date of September 9, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic pharmaceutical for treating autoimmune and...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FT089Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $52,499.06 to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL. This is a competitively awarded, firm fixed-price delivery order with no set-aside designation and an ultimate completion date of October 21, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic immunosuppressant medication commonly prescribed for autoimmune conditions, and this order supports the federal government's pharmaceutical supply chain for military and veteran healthcare systems. This delivery order represents a single transaction under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999 million through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal medical procurement and maintains an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The company's positioning as a prime vendor within DLA's Pharmaceutical Prime Vendor Global Program enables it to efficiently fulfill medical supply needs for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $52.5k | 10/20/25 |